Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 23 trials in our China, USA, Australia, France, Spain, Denmark, Poland, Norway, Canada, Belgium, Netherlands and Egypt registers that name Rapamycin as an intervention.Synced 9 Nov 2026
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov registry records · Synced · Editorial standards
At a glance
Rapamycin is named as an intervention in 23 current clinical trials
in our China, USA, Australia, France, Spain, Denmark, Poland, Norway, Canada, Belgium, Netherlands and Egypt registers.
16 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Umoja Biopharma (2). The most-studied condition is Lymphatic Malformation.
Patient leaflets for Rapamycin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
FDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
23 current trials in our China, USA, Australia, France, Spain, Denmark, Poland, Norway, Canada, Belgium, Netherlands and Egypt registers name Rapamycin as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Rapamycin trials recruiting patients?
Yes. 16 of the 23 trials are recruiting: 6 with sites in China, 3 with sites in USA, 1 with sites in Australia, 2 with sites in France, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in Norway, 1 with sites in Canada, 1 with sites in Belgium and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Rapamycin clinical trials?
Umoja Biopharma (2), AFT Pharmaceuticals, Ltd (1), AgelessRx (1) and Peking Union Medical College (1), among 22 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rapamycin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rapamycin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rapamycin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.
Please verify before you rely on this.
This page is general information for life-science and pharmaceutical professionals. It is
not medical advice, and it has not been reviewed by a clinician — our editorial
team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most
recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC)
and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not
automatically interchangeable, and approvals, brand names and indications differ between the US, the
EU/Ireland (EMA/HPRA) and other regions.
Spotted an error? Tell us — we correct promptly and log it.
We value your privacy
With your consent, we use analytics cookies (Google Analytics and Microsoft Clarity) to understand how the site is used and improve it. We do not show advertising. You can change your choice at any time.
